Key references: Cytomegalovirus prophylaxis in immunocompromised adults without HIV infection

  • Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355(9220):2032–6. https://www.ncbi.nlm.nih.gov/pubmed/10885354
  • Finlen Copeland CA, Davis WA, Snyder LD, Banks M, Avery R, Davis RD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant 2011;30(9):990–6. https://www.ncbi.nlm.nih.gov/pubmed/21489817
  • Hodson EM, Ladhani M, Webster AC, Strippoli GF, Craig JC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013;(2):CD003774. https://www.ncbi.nlm.nih.gov/pubmed/23450543
  • Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10(5):1228–37. https://www.ncbi.nlm.nih.gov/pubmed/20353469
  • Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010;90(12):1427–31. https://www.ncbi.nlm.nih.gov/pubmed/21197713
  • Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6(9):2134–43. https://www.ncbi.nlm.nih.gov/pubmed/16780548
  • Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation 2018. https://www.ncbi.nlm.nih.gov/pubmed/29596116
  • Martin-Gandul C, Perez-Romero P, Sanchez M, Bernal G, Suarez G, Sobrino M, et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol 2013;56(1):13–8. https://www.ncbi.nlm.nih.gov/pubmed/23131346
  • Monforte V, Lopez C, Santos F, Zurbano F, Sole A, et al. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Am J Transplant 2009;9(5):1134–41. https://www.ncbi.nlm.nih.gov/pubmed/19344437
  • Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013;(2):CD005133. https://www.ncbi.nlm.nih.gov/pubmed/23450558
  • Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010;152(12):761–9. https://www.ncbi.nlm.nih.gov/pubmed/20547904
  • Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4(4):611–20. https://www.ncbi.nlm.nih.gov/pubmed/15023154
  • Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:93–106 .[PubMed]
  • Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006;43(7):869–80. https://www.ncbi.nlm.nih.gov/pubmed/16941368
  • Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 2010;90(4):412–8. https://www.ncbi.nlm.nih.gov/pubmed/20555305
  • Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15(10):1143–238. https://www.ncbi.nlm.nih.gov/pubmed/19747629
  • Trevillyan J, Angus P, Shelton E, Whitlam J, Ierino F, Pavlovic J, et al. Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir. Antimicrob Agents Chemother 2013;57(8):4058–60. https://www.ncbi.nlm.nih.gov/pubmed/23733466
  • Volin L, Barkholt L, Nihtinen A, Aschan J, Uotinen H, et al. An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41(1):S47. https://www.nature.com/bmt/volumes/41/issues/1#Supplement
  • Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012;93(1):61–8. https://www.ncbi.nlm.nih.gov/pubmed/22094954